

24. BÖLÜM

KANSER TEDAVİSİNDE KARDİYAK TOKSİSİTELERE YAKLAŞIM

Hasan Burak İŞLEYEN¹
Sevil TUĞRUL YAVUZ²

GİRİŞ

Günümüz gelişen sosyo-ekonomik durum ve bilimin teknolojiye yansımalarından dolayı hastalıkların tanı, takip ve tedavileri bir önceki dekada göre daha iyi bir şekilde düzenlenebilmektedir. Bu durum tıbbın genel sağlık problemlerine çözüm getirme olasılığını artırmıştır.

Diğer tüm tıp alanlarında olduğu gibi onkoloji ve kardiyoloji hastalarının yaşam süresi de uzamaktadır. Bu durum biz hekimleri giderek artan sıklıklarda ortak kesişim kümesi olan hastalar ile karşı karşıya getirmektedir.

Kemoterapiler sonrası meydana gelen kardiyotoksiste tedavinin sık kardiyak komplikasyonları sonucu zamanla ve elde edilen tecrübeler ışığında kardiyologların da tedavi ve takibe dahil olmasını gerektirmiştir. Durum sadece bununla da kalmıyor ilk ve değerlendirmeden yaşam sonuna dek döngüde kardiyoloji ve onkolojinin oluşturduğu bir ekibin varlığını kaçınılmaz hale getiriyor. Bu bütünleyici ekibe kardiyonkoloji ekibi denilir.

KEMOTERAPİ VE RADYASYON TEDAVİSİNE BAĞLI KARDİYOTOKSİSİTEYE GENEL BAKIŞ

Son yıllarda birçok kanser türü tedavisine yönelik spesifik ilaçlar önemli ölçüde artmıştır.

Klasik hücre döngüsü kinetiğine dayalı ilaçların yanı sıra önemli sinyalizasyon yollarının özel hedeflenmesi ile de hücre çoğalması engellenebilir. Bun-

¹ Uzm. Dr., SBU İstanbul Bağıcılar Eğitim ve Araştırma Hastanesi Kardiyoloji Kliniği
isleyenburak44@gmail.com

² Uzm. Dr., SBU Başakşehir Çam ve Sakura Şehir Hastanesi seviltugrul@hotmail.com

KAYNAKLAR

1. Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. *International journal of radiation oncology, biology, physics*. 2000; 48:169–179.
2. Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. *Journal of the American College of Cardiology*. 2013
3. Aapro M, Bernard-Marty C, Brain EG, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2011; 22:257–267. [PubMed: 20956616]
4. Serrano C, Cortes J, De Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2012; 23:897–902. [PubMed: 21828361]
5. Tarantini L, Gori S, Faggiano P, et al. Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2012; 23:3058–3063. [PubMed: 22700991]
6. Cardinale D, Colombo A, Lamantia G, et al. Cardio-oncology: a new medical issue. *Ecan-cermedicalsience*. 2008; 2:126. [PubMed: 22275992]
7. Albin A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio oncological prevention. *Journal of the National Cancer Institute*. 2010; 102:14–25. [PubMed: 20007921]
8. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. *Journal of the American College of Cardiology*. 2009; 53:2231–2247. [PubMed: 19520246]
9. Coleman RE, Maisey MN, Knight RK, Rubens RD. Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity. *European journal of cancer & clinical oncology*. 1984; 20:771–776. [PubMed: 6540179]
10. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. *Drug safety : an international journal of medical toxicology and drug experience*. 2000; 22:263–302.
11. Cerny J, Hassan A, Smith C, Piperdi B. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. *Clinical colorectal cancer*. 2009; 8:55–58. [PubMed: 19203898]
12. Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2012; Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. 23:791–800. [PubMed: 21665955]
13. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. *Circulation*. 2004; 109:3122–3131. [PubMed: 15226229]
14. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. *Mayo Clinic proceedings*. Mayo Clinic. 2008; 83:679–686.
15. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. *Lancet*. 2007; 370:2011–2019. [PubMed: 18083403]
16. Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2009; 20:1535–1542. [PubMed: 19474115]
17. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2008; 19:1613–1618. [PubMed: 18436521]

18. Hall PS, Harshman LC, Srinivas S, Witteles RM. The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients. *JACC Heart Fail.* 2013; 1:72–78. [PubMed: 24621801]
19. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *The New England journal of medicine.* 2013; 369:722–731. [PubMed: 23964934]
20. Kruit WH, Punt KJ, Goey SH, et al. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication. *Cancer.* 1994; 74:2850–2856. [PubMed: 7954247]
21. Leighl NB, Raez LE, Besse B, et al. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinumand erlotinib-resistant adenocarcinoma of the lung. *J Thorac Oncol.* 2010; 5:1054–1059. [PubMed: 20593550]
22. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. *Ophthalmology.* 2012; 119:1658–1665. [PubMed: 22537617]
23. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2005; 23:2900–2902. [PubMed: 15860848]
24. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. *J Cardiovasc Magn Reson.* 2008; 10:5. [PubMed: 18272009]
25. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. *Journal of the American College of Cardiology.* 2010; 55:213–220. [PubMed: 20117401]
26. Sawaya H, Plana JC, Scherrer-Crosbie M. Newest echocardiographic techniques for the detection of cardiotoxicity and heart failure during chemotherapy. *Heart failure clinics.* 2011; 7:313–321. [PubMed: 21749883]
27. Curigliano, G.; Cardinale, D.; Suter, T., et al. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.* Vol. 23. Suppl 7: 2012. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.; p. vii155-166.
28. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2002; 20:1215–1221. [PubMed: 11870163]
29. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *The New England journal of medicine.* 2000; 342:1077–1084. [PubMed: 10760308]
30. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ than cancer? Fiveyear survival following a first admission for heart failure. *European journal of heart failure.* 2001; 3:315–322. [PubMed: 11378002]
31. Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. *Cancer treatment reports.* 1978; 62:955–961. [PubMed: 352510]
32. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. *Annals of internal medicine.* 1996; 125:47–58. [PubMed: 8644988]
33. Berry GJ, Jorden M. Pathology of radiation and anthracycline cardiotoxicity. *Pediatric blood & cancer.* 2005; 44:630–637. [PubMed: 15825155]
34. Minotti G, Cairo G, Monti E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song? *FASEB journal : official publication of the Federation of American Societies for Experimental Biology.* 1999; 13:199–212. [PubMed: 9973309]
35. Lebrecht D, Walker UA. Role of mtDNA lesions in anthracycline cardiotoxicity. *Cardiovascular toxicology.* 2007; 7:108–113. [PubMed: 17652814]
36. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. *Cell biology and toxicology.* 2007; 23:15–25. [PubMed: 17009097]

37. Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ. Emerging paradigms in cardiomyopathies associated with cancer therapies. *Circulation research*. 2013; 113:754–764. [PubMed: 23989717]
38. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nature medicine*. 2012; 18:1639–1642.
39. Katayama M, Imai Y, Hashimoto H, et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. *J Cardiol*. 2009; 54:330–334. [PubMed: 19782276]
40. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. *Archives of internal medicine*. 1981; 141:758–763. [PubMed: 7235784]
41. Hariharan S, Lowry S. Cardiotoxicity associated with sunitinib. *Lancet*. 2008; 371:1244–1245. author reply 1245. [PubMed: 18406854]
42. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. *Nature reviews. Cardiology*. 2010; 7:564–575.
43. Kerkela R, Woulfe KC, Durand JB, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. *Clinical and translational science*. 2009; 2:15–25. [PubMed: 20376335]
44. Greineder CF, Kohnstamm S, Ky B. Heart failure associated with sunitinib: lessons learned from animal models. *Current hypertension reports*. 2011; 13:436–441. [PubMed: 21826469]
45. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. *Circulation*. 2007; 116:954–960. [PubMed: 17709650]
46. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. *Nature medicine*. 2002; 8:459–465.
47. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011; 29:632–638. [PubMed: 21205755]
48. Hawkes EA, Okines AF, Plummer C, Cunningham D. Cardiotoxicity in patients treated with bevacizumab is potentially reversible. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011; 29:e560–562. [PubMed: 21606423]
49. Giordano FJ, Gerber HP, Williams SP, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. *Proceedings of the National Academy of Sciences of the United States of America*. 2001; 98:5780–5785. [PubMed: 11331753]
50. Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non invasive imaging for detection of cardiovascular disease. *European heart journal*. 2013
51. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *The New England journal of medicine*. 2013; 368:987–998. [PubMed: 23484825]
52. van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2012; 30:1429–1437. [PubMed: 22473161]
53. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2010; 28:1308–1315. [PubMed: 20142603]
54. Wu W, Masri A, Popovic ZB, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. *Circulation*. 2013; 127:1476–1484. [PubMed: 23569119]
55. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. *BMJ*. 2009; 339:b4606. [PubMed: 19996459]

56. Stewart JR, Fajardo LF, Gillette SM, Constone LS. Radiation injury to the heart. *International journal of radiation oncology, biology, physics*. 1995; 31:1205–1211.
57. van Leeuwen-Segarceanu EM, Bos WJ, Dorresteijn LD, et al. Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease. *Cancer treatment reviews*. 2011; 37:391–403. [PubMed: 21333452]
58. Lee PJ, Mallik R. Cardiovascular effects of radiation therapy: practical approach to radiation therapy-induced heart disease. *Cardiology in review*. 2005; 13:80–86. [PubMed: 15705258]
59. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. *Human pathology*. 1996; 27:766–773. [PubMed: 8760008]
60. Seemann I, Gabriels K, Visser NL, et al. Irradiation induced modest changes in murine cardiac function despite progressive structural damage to the myocardium and microvasculature. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2012; 103:143–150. [PubMed: 22112779]
61. Ordovas KG, Higgins CB. Delayed contrast enhancement on MR images of myocardium: past, present, future. *Radiology*. 2011; 261:358–374. [PubMed: 22012903]
62. Hoening MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. *Journal of the National Cancer Institute*. 2007; 99:365–375. [PubMed: 17341728]
63. Ylanen K, Poutanen T, Savikurki-Heikkilä P, Rinta-Kiikka I, Eerola A, Vattenranta K. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among longterm survivors of childhood cancer. *Journal of the American College of Cardiology*. 2013; 61:1539–1547. [PubMed: 23500246]
64. Gabriels K, Hoving S, Seemann I, et al. Local heart irradiation of ApoE(–/–) mice induces microvascular and endocardial damage and accelerates coronary atherosclerosis. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2012; 105:358–364. [PubMed: 22959484]
65. Hoving S, Heeneman S, Gijbels MJ, et al. Irradiation induces different inflammatory and thrombotic responses in carotid arteries of wildtype C57BL/6J and atherosclerosis-prone ApoE(–/–) mice. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2012; 105:365–370. [PubMed: 23245647]
66. Stewart FA, Heeneman S, Te Poele J, et al. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE–/– mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. *The American journal of pathology*. 2006; 168:649–658. [PubMed: 16436678]